Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate-Severe Crohn's Disease.
Scott David LeeKendra KampKindra Dawn Clark-SnustadPublished in: Crohn's & colitis 360 (2022)
Ustekinumab re-induction was well tolerated. Clinical and endoscopic disease activity improved in some patients. Further larger studies are needed to verify these findings in a broader population.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- rheumatoid arthritis patients
- ejection fraction
- newly diagnosed
- chronic kidney disease
- ankylosing spondylitis
- physical activity
- juvenile idiopathic arthritis
- ultrasound guided
- high dose
- low dose
- patient reported outcomes
- weight gain
- drug induced